New evidence reveals global underassessment and undertreatment of chronic hepatitis B (HBV), especially among women and Asian ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) has unveiled its growth during the first quarter of 2024, particularly in the ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Additionally, the presentation of the 48-week end-of-treatment data from the hepatitis B virus (HBV) Phase 2 trial later in the year is viewed as another critical event that could drive the company’s ...

May 2, 2024 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $ ...

It's been a busy month for the liver health community, not least with the release of WHO's global viral hepatitis 2024 report ...

Discover Altimmune Inc's groundbreaking patent for a pharmaceutical composition targeting HBV with peptides containing CD8+ and CD4+ T-cell epitopes. Learn about the innovative intracellular delivery ...

Dagger; Approximately five copies = 1 IU. ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus. IgM anti-HBc Presence with high index value during acute HBV ...

Duke University spinout Tune Therapeutics is rehearsing the overture of its avant-garde therapeutic platform targeting ...

Data from the REAL-B consortium reveal a global underassessment and undertreatment of chronic hepatitis B (HBV), especially among women and Asian minorities in the West.

To stem the rising cases of liver cancers, a Professor of Medicine,, Gastroenterology and Liver Unit, Faculty of Clinical ...

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024Preliminary ...